Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies Influencing My Practice Following IAS 2021—Rapid Recap by Dr. Daniel Kuritzkes

July 18-21, 2021; Virtual
Hear unique insights from CCO’s expert faculty, Dr. Daniel Kuritzkes, as he presents his insights on some of the most clinically relevant new data presented at IAS 2021, including results from studies on HIV and COVID-19 outcomes; virologic and metabolic outcomes of DTG/3TC; long-acting CAB + RPV for ART in treatment-naive PWH; investigational antiretroviral agents, lenacapavir and islatravir; and alternative dosing of BPaL for MDR-TB.
Daniel R. Kuritzkes, MD
Released: August 9, 2021

Information on this Educational Activity

Faculty

Daniel R. Kuritzkes, MD

Chief, Division of Infectious Diseases
Brigham and Women's Hospital
Harriet Ryan Albee Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Daniel R. Kuritzkes, MD, has reported that he has received funds for research support from Atea, Gilead Sciences, Merck, Novartis, and ViiV Healthcare and consulting fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, Rigel, and ViiV Healthcare.

Program Medium

This program has been made available online.

Related Content

Clinical Care Options (CCO) expert analysis of new HIV data from IDWeek 2021, provided by expert HIV faculty

Eric S. Daar, MD Released: October 21, 2021

Expert selections of important HIV data from IDWeek 2021, including current and investigational ART, HIV PrEP, and metabolic outcomes of ART.

Eric S. Daar, MD Darcy Wooten, MD Released: October 19, 2021

Clinical Care Options (CCO) and Dr. Josep Llibre: Perspective on the landscape of ART options for highly treatment-experienced patients with HIV

Josep M. Llibre, MD, PhD Released: October 18, 2021

Dr William Short and Clinical Care Options (CCO): Data fails to support adding agents to intensify ART, switching ART, or adding IL-2 for patients with suboptimal CD4+ cell counts on suppressive ART

William R. Short, MD, MPH, AAHIVS Released: October 15, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue